Highly frequent anti-idiotype antibody in cynomolgus monkeys developed against mouse-derived regions of anti-Fas antibody humanized by complementarity determining region grafting.

BACKGROUND AND PURPOSE: We investigated the immunogenicity of a humanized anti-human Fas monoclonal antibody, R-125224, in cynomolgus monkeys to estimate its efficacy, as well as its toxicity in clinical situations. EXPERIMENTAL APPROACH: R-125224 was intravenously administered to cynomolgus monkeys at single doses of 0.4, 1.2, 6 and 30 mg kg(-1), and the plasma concentrations of R-125224 and anti-R-125224 antibody (ARA) were measured. We conducted a competitive enzyme-linked immunosorbent assay to determine which part of R-125224 was recognized by ARA. We also examined the retention of radioactivity in mononuclear cells and granulocytes after the injection of [(125)I]-R-125224 to a collagen-induced arthritis monkey model. KEY RESULTS: After i.v. administration of R-125224, the elimination of the plasma R-125224 concentrations was accelerated at around 10 days post-dose, and 10 of 12 monkeys were ARA positive. From an epitope analysis of ARA, the ARA produced in monkeys recognized the mouse-derived regions located in complementarity determining regions, but could not recognize the human IgG. After the injection of [(125)I]-R-125224 to a collagen-induced arthritis monkey model, a significantly longer retention of the radioactivity in mononuclear cells compared to granulocytes was observed. CONCLUSIONS AND IMPLICATIONS: In monkeys, the development of antibodies against R-125224 is rapid and highly frequent. Our hypothesis is that this highly frequent development of ARA might be due to the binding of R-125224 to immune cells, and its circulation in monkey blood might contribute to an increase in its chances of being recognized as an immunogen.

Characterization of UDP-glucuronosyltransferases (UGTS) involved in the metabolism of troglitazone in rats and humans.

UDP-glucuronosyltransferases (UGTs) involved in troglitazone glucuronidation in rats and humans have been characterized to support the previous toxicity study on troglitazone in Gunn rats and to examine whether the UGT polymorphism or inhibition of bilirubin metabolism is related to the clinically reported rare cases of liver failure. The experiments using Gunn rats revealed that UGT1 enzymes are not involved in troglitazone glucuronidation and that the responsible enzyme in rats was suggested to be UGT2B2, an androsterone UGT, by inhibition studies. In humans, contribution of UGT1A1 was estimated to be about 30% of the total troglitazone glucuronidation by UGTs, using human liver microsomes and recombinant UGTs. Other UGT1 and UGT2 enzymes seem to be responsible for the rest of the troglitazone glucuronidation in humans. The multiplicity of UGTs involved in troglitazone glucuronidation in humans may allow even patients lacking bilirubin UGT (UGT1A1) activity to produce troglitazone glucuronide. These observations suggest that the polymorphism of UGT is not the reason behind the liver failure induced by the troglitazone treatment, and troglitazone does not inhibit bilirubin glucuronidation in clinical treatment. In addition, the increased bilirubin level in the blood of patients who have troglitazone-induced liver failure is a consequence of liver injury and not due to inhibition of bilirubin glucuronidation by troglitazone.

Characterization of esterases involved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma.

An inhibition study showed that the stereoselective hydrolysis of butyryl propranolol (butyryl PL) in rat liver microsomes and plasma involves carboxylesterase. The hydrolysis of (S)-butyryl PL in plasma was specifically inhibited by eserine and bis-nitrophenyl phosphate (BNPP), compared to the (R)-isomer, despite the non-stereoselective hydrolysis of butyryl PL in plasma. In addition, inhibition of hydroloysis by eserine and BNPP showed little stereoselectivity for butyryl PL in liver, although liver microsomes showed an (S)-preferential hydrolysis for butyryl PL (R/S ratio of Vmax/Km: 2.1 +/- 0.2). The hydrolysis of butyryl PL was not inhibited by a polyclonal antibody against a high affinity carboxylesterase (hydrolase A, RH1). Moreover, the high Km value and the high IC50 for phenylmethylsulfonyl fluoride (PMSF) against the hydrolysis of butyryl PL in rat liver microsomes suggest that a low affinity carboxylesterase (perhaps hydrolase B) might be involved in this hydrolysis in rat liver.

Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa.

The bioavailability of propranolol (PL) after oral administration of ester-type prodrug was compared in rat and dog, and the possible reason for species difference was investigated. In dog, the oral bioavailability of PL was enhanced by the use of prodrug due to saturation of metabolism of PL. In contrast, high (10 mg/kg) and low (2.5 mg/kg) doses of butyryl PL and isovaleryl PL failed to improve oral bioavailability of PL in rats. The hydrolase activities for prodrugs in rat liver were lower than those of dog (by 4-12-fold), but those of rat intestinal mucosa were significantly higher than those of dog (50-260-fold). Although it is clear from the in vitro hydrolysis using subcellular fractions that the rapid hydrolysis in intestinal mucosa was mainly due to cytosolic components, the brush-border membrane vesicle in rat intestine also showed hydrolase activity for both prodrugs. In situ absorption experiment in rat revealed an improvement in the apparent absorption rate of PL as the result of prodrug use (1.3-fold) and the nearly complete hydrolysis of isovaleryl PL during intestinal absorption, which is a slower hydrolyzed prodrug than butyryl PL in intestinal mucosa and liver. The defects for enhancing oral bioavailability in rats appears to be based on an unsaturation of metabolism for PL, which is derived from a decrease in PL concentration in hepatocytes, owing to rapid hydrolysis of the prodrug in intestinal mucosa and slow hydrolysis of the prodrug in liver. Furthermore, human intestinal mucosa showed a surprisingly high hydrolase activity in microsomes. Therefore, the oral bioavailability of PL after administration of prodrugs might be not significantly improved in human.

Species differences in stereoselective hydrolase activity in intestinal mucosa.

PURPOSE: The aim of this study is to investigate species differences in the stereoselective hydrolysis for propranolol ester prodrugs in mammalian intestinal mucosa and Caco-2 cells. METHODS: Hydrolase activities for propranolol prodrugs and p-nitrophenylacetate in man (age: 51-71 years), the beagle dog (age: 4 years) and Wistar rat (age: 8 weeks) intestinal mucosa, and also in Caco-2 cells (passage between 60-70) were estimated by determining the rate of production of proparanolol and p-nitrophenol, respectively. RESULTS: The hydrolase activities for both propranolol prodrugs and p-nitrophenylacetate were in the order of man > rat >> Caco-2 cells > dog for intestinal microsomes, and rat > Caco-2 cells = man > dog for intestinal cytosol. Dog microsomes showed stereoselective hydrolysis for propranolol prodrugs, but not those from human or rat. Interestingly, both subcellular fractions of Caco-2 cells showed remarkable R-enantioselectivity except acetyl propranolol. Enzyme kinetic experiments for each enantiomer of butyryl propranolol in microsomes revealed that dog possesses both low and high affinity hydrolases. Both Km and Vmax values in rat were largest among examined microsomes, while Vmax/Km was largest in man. Finally, it was shown that the carboxylesterases might contribute to the hydrolysis of propranolol prodrug in all species by inhibition experiments. CONCLUSIONS: The hydrolase activities for propranolol prodrugs and p-nitrophenylacetate in intestinal mucosa showed great species differences and those in human intestine were closer to those of rat intestine than dog intestine or Caco-2 cells.

Stereospecific activity and nature of metabolizing esterases for propranolol prodrug in hairless mouse skin, liver and plasma.

Cutaneous stereoselective hydrolyses of ten ester prodrugs of propranolol in hairless mouse were compared to those in liver and plasma. On the basis of protein content, the hydrolysis rate was greatest with liver homogenate followed by plasma and skin homogenate. The buffer showed the slowest and non-stereoselective hydrolysis. However, skin showed very high stereoselectivity (R/S ratio: 6.7-18.4) as compared with liver (0.7-2.0) and plasma (1.7-4.7). The microsomal esterase activity was higher than cytosolic esterase in liver, while an opposite relation was observed in skin. The smaller Km and larger Vmax values of the (R) isomer than those of the (S) isomer of caproyl- and/or butyryl-propranolol were found in skin and plasma, while Km was the same between (R) and (S) isomers in liver. Enzyme inhibition studies indicated that the carboxylesterases were primarily involved in prodrug hydrolysis in liver. On the other hand, skin and plasma were found to be rich in both carboxylesterases and cholinesterases. Interestingly, the (R) isomer was more sensitive towards butylcholinesterase in skin and plasma, while (S) isomer was more sensitive towards carboxylesterase in plasma. Moreover, no stereoselective inhibition was observed in liver. These data indicated that the hydrolyzing nature of skin esterases responsible for propranolol prodrug was sensitive against stereochemical configuration and more similar to those in plasma esterases than liver esterases.

Species differences for stereoselective hydrolysis of propranolol prodrugs in plasma and liver.

Species differences and substrate specificities for the stereoselective hydrolysis of fifteen O-acyl propranolol (PL) prodrugs were investigated in pH 7.4 Tris-HCl buffer and rat and dog plasma and liver subfractions. The (R)-isomers were preferentially converted to propranolol (PL) in both rat and dog plasma with the exception of isovaleryl-PL in rat plasma, although the hydrolytic activities of prodrugs in rat plasma were 5-119-fold greater than those in dog plasma. The prodrugs with promoieties (C(=O)CH(R)CH3) based on propionic acid showed marked preference for hydrolysis of the (R)-enantiomers in plasma from both species (R/S ratio 2.5-18.2). On the other hand, the hepatic hydrolytic activities of prodrugs were greater in dog than rat, especially in cytosolic fractions. The hydrolytic activity was predominantly located in microsomes of the liver in rat, while the cytosol also contributed to hepatic hydrolysis in dog. Hepatic microsomal hydrolysis in dog showed a preference for the (R)-isomers except acetyl- and propionyl-PL. Interestingly, in rat liver all types of prodrugs with substituents of small carbon number showed (S)-preference for hydrolysis. The hydrolyses of (R)- and (S)-isomers of straight chain acyl esters in rat liver microsomes were linearly and parabolically related with the carbon number of substituents, respectively, while these relationships were linear for both isomers in dogs.

Stereoselective hydrolysis of O-isovaleryl propranolol and its influence on the clearance of propranolol after oral administration.

The stereoselective hydrolysis of O-isovaleryl propranolol (isovaleryl-PL) was studied using phosphate and Tris-HCl buffers (pH 7.4), dog plasma, and liver preparations. The 10000g supernatant, microsomes, and cytosol were prepared from the liver homogenate. The hydrolysis rate of isovaleryl-PL was accelerated in the order Tris buffer < plasma = phosphate buffer << 10000g supernatant of liver = liver cytosol < liver microsomes. The high plasma protein binding of the prodrug brought about the extremely slow hydrolysis rate of isovaleryl-PL in plasma. No difference was observed in the hydrolysis rate between the isomers of isovaleryl-PL in buffers. The hydrolysis rate was 2-3 times faster with the (R)-isomer than with the (S)-isomer using racemate in dog plasma and liver preparations. The hydrolysis of each enantiomer was inhibited by the other enantiomer. For hydrolysis in microsomes the Km values of (R)- and (S)-isomers were same, and the Vmax of the (R)-isomer was 3 times greater than that of the (S)-isomer. These data suggested the mutual interaction of (R)- and (S)-isomers during the hydrolysis process and the rapid hydrolysis of isovaleryl-PL in liver after absorption. The AUC of PL enantiomers after oral administration of racemic isovaleryl-PL was about 2 times higher compared to 2 mg/kg equivalent molar dose of racemic PL in beagle dogs, and the corresponding plasma levels were not stereoselective from both PL and prodrug. The amount of (R)-PL absorbed after administration of a 5 mg/kg dose of racemic PL was 2-fold greater than (S)-PL, because of the stereoselective oxidation and glucronidation of (S)-PL.(ABSTRACT TRUNCATED AT 250 WORDS)